The Arise2 trial in the USA is one of the first to look at a new treatment for Idiopathic Hypersomnia, and is still recruiting participants across mainland USA. Pentetrazol – known as BTD-001 – has already seen limited trials for Narcolepsy Type 2, and works as a GABA antagonist (or blocker).
The NHS are monitoring the trial too which is a good sign.